Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good times are coming here
Oct 13, 2012 Issued an alert on BMSN.
InsideBulls.com Profiles The Best Penny Stock Picks: (PINKSHEETS: BIEL), (OTCQB: PHOT), (OTCQB: BMSN), (OTCBB: GTXO)
www.InsideBulls.com is issuing a volume alert on the following stocks (PINKSHEETS: BIEL), (OTCQB: PHOT), (OTCQB: BMSN), (OTCBB: GTXO)
NEW YORK, NY, Oct 13, 2012 (eTeligis.com via COMTEX) Your online resource for microcap stock news and information, Insidebulls.com offers a free newsletter featuring some of the best penny stock picks available. Our sole purpose is to find the best penny stock picks and keep you informed with fast moving penny stocks. To receive our amazing penny stock newsletter and alerts go to http://insidebulls.com/
***The following Penny Stocks are active this week:***
BioElectronics Corporation (PINKSHEETS: BIEL) is an award winning developer and manufacturer of advanced medical devices. Its products are ActiPatch Therapy, for over-the-counter treatment of back pain and other musculoskeletal ailments, the Allay(TM) Menstrual Cycle Pain Therapy, and RecoveryRx(TM) for surgical procedures and wound care. The unique therapy delivery system, using patented technology, provides a cost-effective home care to reduce soft tissue pain and accelerate healing. For the Best Penny Stock Picks Subscribe to http://www.insidebulls.com/
GrowLife, Inc. (OTCQB: PHOT) is a company with core holdings in innovative technology-based products and services for the indoor gardening industry and specialty markets. These brands include Stealth Grow LED producer of hi-powered LED grow light products for indoor horticulture. For the Best Penny Stock Picks Subscribe to http://www.insidebulls.com/
Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) is a biotechnology research and development company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories. For the Best Penny Stock Picks Subscribe to http://www.insidebulls.com/
GTX Corp (OTCBB: GTXO) a leader in enterprise 2 way GPS real-time personal location services (PLS) was founded in 2002 and is based in Los Angeles, California with distributors in Mexico, Australia and Nepal and customers in 159 countries. GTX Corp utilizes the latest in miniaturized, low power consumption technology and offers a robust enterprise GPS and cellular location platform to track in real time the whereabouts of people, pets, vehicles and high valued assets. For the Best Penny Stock Picks Subscribe to http://www.insidebulls.com/
Please visit http://insidebulls.com/ for complete risks and disclosures.
Contact: InsideBulls.com / info@insidebulls.com
We've seen it open at .008 just recently with no news so you are very correct we could see this open at a penny with news.
Entest BioMedical, Inc. Sees Entry Into $300 Million Veterinary Cancer Care Market Through Veterinary Hospital Acquisitions
Print
Alert
Entest Biomedical Inc. (QB) (USOTC:ENTB)
Historical Stock Chart
2 Months : From Aug 2012 to Oct 2012
Entest BioMedical Inc. (PINKSHEETS: ENTB) (OTCQB: ENTB) a company focused on veterinary biotechnology and veterinary hospital acquisition / operation, announced today that it has begun the process of interviewing qualified candidates to fill the Company's newly created position of Director of Corporate Affairs.
A Company spokesman stated that, "The primary responsibilities of the Director of Corporate Affairs shall be to identify veterinary hospitals suitable for acquisition, substantially assist in the structuring of those acquisitions, and work with the company to integrate newly acquired veterinary hospitals into the Company. The Company's current business model involves acquiring veterinary clinics / hospitals to be utilized as potential distribution channels for its products under development. The Company believes that, in addition to serving as distribution channels for the Company's immuno-therapeutic cancer vaccine for canines, these clinics will be able to generate revenue for the Company from current operations."
"Our primary goal is to continue growing the number of Veterinary Hospitals we own," stated Dr. David Koos, Chairman and CEO of Entest BioMedical. "In pursuing this segment of our business model, we will be able to continue growing our asset base, increase our current revenue stream and establish an initial distribution channel for our products and therapies; the first of these products being Entest's ImenVax immune-therapeutic canine cancer vaccine currently under development. Having a qualified Director of Corporate Affairs whose duties will consist primarily of identifying hospitals for acquisition and who possesses the skills required to substantially assist us in negotiating favorable purchase terms will be valuable in assisting the Company in achieving its goal of acquiring up to 10 additional veterinary clinics within the next 16 months." Entest currently owns and operates the McDonald Animal Hospital of Santa Barbara, CA which the company purchased in 2011. This facility serves as both a revenue source for Entest as well as a research facility for the biomedical company.
Dr. Koos continued, "One in every three dogs will develop cancer during its lifetime. Sadly, such cancers kill nearly half of all pet dogs over the age of ten; animals that are family to millions of pet owners. Pet owners are willing to pay the cost for the necessary treatments meant to save the lives of their loved ones. We believe we will be able to provide families the needed cancer therapies for their canines, within the appropriate facilities, should we continue pursuing our growth model. With the ASPCA citing approximately 78 million dogs as pets within the United States, the veterinary care market represents enormous revenue potential. It has been estimated that the U.S. market for veterinary cancer care amounts to approximately $300 million per year."
Dr. Koos concluded, "Canine cancer impacts 60% of all dogs over six years of age in the United States (http://dogcanceradvice.com/canine-cancer-information/overview/). Cancer in canines is still predominantly treated through surgical excision, chemotherapy and radiation therapy. These treatment methods can be highly invasive and can result in numerous unpleasant side effects. We believe our products under development, which utilize the patient's own immune system to battle the cancer, will be able to offer a lower cost, less traumatic alternative to veterinarians and pet owners. As both the CEO of Entest and a loving pet owner my objectives are twofold; to contribute economic value to Entest as well as to contribute to the lifelong happiness of families who are pet owners."
Nice green close on a Friday. Lovely! Can't wait to see what happens Monday. There are lot's of eyes on ENTB and this might just be the start of our assent to .05!
We just got a PR.
Sorry when I google that I get "do you mean "chemxlerate" and the IHUB post after that.
I don't think many people have heard this news, remember it's been out for a week and we just saw it today. I have etrade and it doesn't show on etrade, it's not on IHub and it doesn't even come up when you google it.
I like the way you think! I was also thinking that perhaps they don't want the news to spread too fast. There has been some very visible accumulation going on here for some time and looks to me like it is still going on.
BMSN BIG NEWS!!!! UP 15% Today
http://www.prweb.com/releases/2012/10/prweb9972993.htm
Bio-Matrix Scientific Group's Regen BioPharma Subsidiary Announces HemaXellerate™ As First Product in Development
Company seeks to enter $18 billion market for bone marrow stimulating growth factors
San Diego, CA (PRWEB) October 03, 2012
Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) announced today that its wholly owned subsidiary, Regen BioPharma, Inc. has begun development of HemaXellerate™, its first clinical product. HemaXellerate™ is a cellular drug designed to heal damaged bone marrow. Typically, bone marrow is damaged by chemotherapy, radiation therapy, or diseases such as anemia.
As part of the development process, on May 18, 2012, Regen submitted a provisional patent application covering the use of placentally-derived endothelial cells for treatment of bone marrow failure. Regen has also been granted an exclusive option to enter into an agreement to be granted an exclusive, worldwide, royalty bearing license to US patent No. 6,821,513, covering a proprietary method for enhancing hematopoiesis (formation of blood cells).
“Current approaches to treating bone marrow disorders involve administration of pharmaceuticals which target stem cells to produce more blood. This approach is not effective on everyone with bone marrow failure and some forms of this disease are completely resistant” said J. Christopher Mizer, President of Regen BioPharma. “Our strategy is to heal the bone marrow by administering cells that provide the optimum mix of growth factors to stimulate the bone marrow into producing blood cells naturally.”
Data from a peer reviewed publication (Lei et al. Stem Cell Res. 2010 January; 4(1): 17–24) by the inventor of the patent demonstrated that the administration of endothelial cells restores blood production and extends survival after bone marrow damage.
“The HemaXellerate™ product aims to address the unmet medical need of patients who are non-responsive to existing growth factor therapies such as Neupogen and Leukine. These patients include those suffering from: aplastic anemia, a condition where the bone marrow produces an insufficient number of new cells to replace lost blood cells; chemotherapy/radiotherapy induced bone marrow failures; and low blood cell production after bone marrow or cord blood transplants,” stated Thomas Ichim, Chief Scientific Officer of Regen BioPharma.
According to David Koos, Chairman & CEO of Bio-Matrix, “HemaXellerate™ may provide an ideal therapeutic for bone marrow failure based upon: (1) regulating secretion of cytokines as biologically needed; (2) producing long-term, localized growth factors that alleviate the need for drugs; and (3) actively repairing the blood producing stem cell environment.”
A spokesperson for the Company said Regen intends to file an Investigational New Drug (IND) Application in the fourth quarter of 2012 and conduct Phase I/II clinical trials during 2013 and 2014.
About Bio-Matrix Scientific Group Inc. and Regen BioPharma, Inc.:
Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) is a biotechnology company developing regenerative medicine therapies and tools. The Company is focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to cardiovascular, hematology, oncology and other indications.
Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN), is a biotechnology company focused on identifying undervalued regenerative medicine patents in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. To follow our development, visit us at http://www.regenbiopharma.com.
Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks
Contact Information
Contact:
Bio-Matrix Scientific Group, Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
619-702-1404
http://www.bmsn.us
dkoos(at)bmsn.us
http://www.prweb.com/releases/2012/10/prweb9972993.htm
I agree!
Maybe ENTB will get news today
I'm always looking for news on OTC markets, I even posted the 8k last week and didn't see this news at that time. Really strange, but none the less this is still huge news!
Did any one see this news a week ago? I didn't.
Bio-Matrix Scientific Group's Regen BioPharma Subsidiary Announces HemaXellerate(TM) As First Product in Development
San Diego, CA, Oct 03, 2012 (PRWeb.com via COMTEX) -- Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) announced today that its wholly owned subsidiary, Regen BioPharma, Inc. has begun development of HemaXellerate(TM), its first clinical product. HemaXellerate(TM) is a cellular drug designed to heal damaged bone marrow. Typically, bone marrow is damaged by chemotherapy, radiation therapy, or diseases such as anemia.
As part of the development process, on May 18, 2012, Regen submitted a provisional patent application covering the use of placentally-derived endothelial cells for treatment of bone marrow failure. Regen has also been granted an exclusive option to enter into an agreement to be granted an exclusive, worldwide, royalty bearing license to US patent No. 6,821,513, covering a proprietary method for enhancing hematopoiesis (formation of blood cells).
"Current approaches to treating bone marrow disorders involve administration of pharmaceuticals which target stem cells to produce more blood. This approach is not effective on everyone with bone marrow failure and some forms of this disease are completely resistant" said J. Christopher Mizer, President of Regen BioPharma. "Our strategy is to heal the bone marrow by administering cells that provide the optimum mix of growth factors to stimulate the bone marrow into producing blood cells naturally."
Data from a peer reviewed publication (Lei et al. Stem Cell Res. 2010 January; 4(1): 17-24) by the inventor of the patent demonstrated that the administration of endothelial cells restores blood production and extends survival after bone marrow damage.
"The HemaXellerate(TM) product aims to address the unmet medical need of patients who are non-responsive to existing growth factor therapies such as Neupogen and Leukine. These patients include those suffering from: aplastic anemia, a condition where the bone marrow produces an insufficient number of new cells to replace lost blood cells; chemotherapy/radiotherapy induced bone marrow failures; and low blood cell production after bone marrow or cord blood transplants," stated Thomas Ichim, Chief Scientific Officer of Regen BioPharma.
According to David Koos, Chairman & CEO of Bio-Matrix, "HemaXellerate(TM) may provide an ideal therapeutic for bone marrow failure based upon: (1) regulating secretion of cytokines as biologically needed; (2) producing long-term, localized growth factors that alleviate the need for drugs; and (3) actively repairing the blood producing stem cell environment."
A spokesperson for the Company said Regen intends to file an Investigational New Drug (IND) Application in the fourth quarter of 2012 and conduct Phase I/II clinical trials during 2013 and 2014.
About Bio-Matrix Scientific Group Inc. and Regen BioPharma, Inc.:
Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) is a biotechnology company developing regenerative medicine therapies and tools. The Company is focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to cardiovascular, hematology, oncology and other indications. Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN), is a biotechnology company focused on identifying undervalued regenerative medicine patents in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. To follow our development, visit us at http://www.regenbiopharma.com. Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks
Contact Information
Contact:
Bio-Matrix Scientific Group, Inc. David R. Koos, PhD Chairman & Chief Executive Officer 619-702-1404 http://www.bmsn.us dkoos(at)bmsn.us
Read the full story at http://www.prweb.com/releases/2012/10/prweb9972993.htm
URL: PRWeb.com
PRWEB.COM Newswire
-0-
I can't seem to find the news any where yet, but this awesome news! Especially for cancer patients. Wow I can't wait to read it myself.
Yup a lot of people will be caught chasing when this starts running. Cause when this runs it runs fast. Float is pretty low.
Cancer treatment, who doesn't want a piece of that!
Entb has made statements that a buyout is on the horizon. Some say that this buyout will bring this here PPS to around a buck a piece for us
Big News coming here soon IMO
Entb UP 18.75% now running to .01+
"Entb's old accounting firm quitting for lack of pay is BAD NEWS for entb and just another company in addition to the other law suites pending that open entb up for further libility."
Letter from former CPA
Dear Sir/Madam:
I have read the statements included under Item 4.01 in the Form 8-K dated September 27, 2012 of Entest Biomedical, Inc. (the "Company") to be filed with the Securities and Exchange Commission and I agree with such statements insofar as they relate to my dismissal. I cannot confirm or deny the appointment of Anton and Chia,
Very truly yours,
John Kinross-Kennedy, CPA
Doesn't sound like someone who quit for lack of pay!
the Board of Directors of Entest BioMedical, Inc. (the “Registrant” or the “Company”) approved of the dismissal of John Kinross-Kennedy, CPA
BUY ENTB! BUY BUY BUY!
Letter from former CPA
Dear Sir/Madam:
I have read the statements included under Item 4.01 in the Form 8-K dated September 27, 2012 of Bio-Matrix Scientific Group, Inc. (the "Company") to be filed with the Securities and Exchange Commission and I agree with such statements insofar as they relate to my dismissal. I cannot confirm or deny the appointment of Anton and Chia,
Very truly yours,
John Kinross-Kennedy
Doesn't sound like someone who quit for lack of pay. Sounds guilty as charged! LOL
BUY BUY BUY
"the only reason entb got another accounting firm is it is the law that entb must have an independant accounting firm to process the books and balance sheets"
It is certainly good to know that ENTB is law abiding and is staying on top of books and balance sheets. I know a lot of pennies who don't give a crap, especially if they were just about to go bankrupt as you have stated here many times.
Experts are saying that this is a BUY BUY BUY.
On September 27, 2012, the Board of Directors of the Registrant, acting as the Registrant's Audit Committee, approved the engagement of Anton and Chia, LLP as its independent auditor. On same date, September 27, 2012, the accounting firm of Anton and Chia, LLP was engaged as the Registrant's new independent registered public accounting firm.
On September 27, 2012, the Board of Directors of the Registrant, acting as the Registrant's Audit Committee, approved the engagement of Anton and Chia, LLP as its independent auditor. On same date, September 27, 2012, the accounting firm of Anton and Chia, LLP was engaged as the Registrant's new independent registered public accounting firm.
Good Morning BMSN board! Let's have a great day here today.
I see the pattern
Good job therealtruth10! Go ENTB!
I totally agree Paris. Couldn't have put it better myself!
Don't forget that we are also expecting news about the newly created position of a director of corporate affairs. If anyone doesn't know what a director of corporate affairs does then please google it. There will be better communication between ENTB and share holders when this position is filled. So yeah many good PR's to come.
I am pretty sure that we will get an update about that very soon as well.
Did the PR state that ImenVax cancer vaccine appears to slow down tumor growth? Link please? Could you also please attach the line in the 10 k that states that the company is going bankrupt.
That PR is from this month, and according the recent 10k Entest is averaging 100k in revenues each quarter with just one hospital. That is half a mil annually with just one clinic. They plan on acquiring 10 in the next 16 months. So yeah 10K shows revenue not bankruptcy.
$3000 X 700 cancer patients = $2,100,00 X 10 clinics = 21,000,000 per year! $$$$$$
It's okay. Good to know that we are on the same side here.